Shares of Natco Pharma may remain in focus, as it has reached a settlement with Onyx Therapeutics, Inc on patent litigation related to generic versions of 10-mg, 30-mg and 60-mg of Kyprolis. Natco Pharma has partnered with Breckenridge Pharmaceutical Inc to market the product in the United States. Kyprolis is used to treat adult patients with multiple myeloma (cancer of plasma cells) who have had at least one previous treatment for this disease.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.